Current Rheumatology Reports

, Volume 4, Issue 2, pp 99–107

The genetics of systemic sclerosis

  • Randall W. Johnson
  • Monty B. Tew
  • Frank C. Arnett
Article
  • 72 Downloads

Abstract

The etiopathogenesis of systemic sclerosis (SSc) is unclear. With no definitive evidence supporting an environmental cause, recent attention has focused on genetic factors. Familial clustering and ethnic influences have been demonstrated. Human leukocyte antigen (HLA) associations exist but are more related to the presence of particular autoantibodies rather than to the disease. In addition, no single major histocompatibility complex (MHC) allele predisposes to SSc in all ethnic groups. The role of microchimerism in SSc is a novel yet unproven hypothesis that may be related to intergenerational HLA compatibility. Recent studies investigating polymorphisms in genes coding for extracellular matrix proteins and cell-signaling molecules implicate non-MHC areas in SSc pathogenesis. The data reviewed suggest that SSc is a multigenic complex disorder.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Mayes MD: Epidemiologic studies of environmental agents and systemic autoimmune diseases. Environ Health Perspect 2000, 107:743–748. A critical review of epidemiologic studies that demonstrates a lack of evidence supporting an environmental exposure significantly contributing to the development to systemic sclerosis.CrossRefGoogle Scholar
  2. 2.
    Feghali CA, Wright TM: Epidemiologic and clinical study of twins with scleroderma [abstract]. Arthritis Rheum 1995, 38:S308.Google Scholar
  3. 3.
    McHugh NJ, Harvey GR, Whyte J, et al.: Segregation of autoantibodies with disease in monozygotic twin pairs discordant for systemic sclerosis: three further cases. Arthritis Rheum 1995, 38:1845–1850.PubMedCrossRefGoogle Scholar
  4. 4.
    Arnett FC: HLA and autoimmunity in scleroderma (systemic sclerosis). Int Rev Immunol 1995, 12:107–128.PubMedGoogle Scholar
  5. 5.
    Arnett FC, Howard RF, Tan FK, et al.: Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma: association with an Amerindian HLA haplotype. Arthritis Rheum 1996, 39:1362–1370.PubMedCrossRefGoogle Scholar
  6. 6.
    Kuwana M, Kaburaki J, Arnett FC, et al.: Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis Rheum 1999, 42:465–474.PubMedCrossRefGoogle Scholar
  7. 7.
    Siracusa LD, McGrath R, Ma Q, et al.: A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res 1996, 6:300–313.PubMedGoogle Scholar
  8. 8.
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980, 23:581–590.CrossRefGoogle Scholar
  9. 9.
    Tan FK, Arnett FC: Genetic factors in the etiology of systemic sclerosis and Raynaud phenomenon. Curr Opin Rheumatol 2000, 12:511–519.PubMedCrossRefGoogle Scholar
  10. 10.
    Mayes MD: Scleroderma epidemiology. Rheum Dis Clin North Am 1996, 22:751–764.PubMedCrossRefGoogle Scholar
  11. 11.
    Manolios N, Dunckley H, Chivers T, et al.: Immunogenetic analysis of 5 families with multicase occurrence of scleroderma and/or related variants. J Rheumatol 1995, 22:85–92.PubMedGoogle Scholar
  12. 12.
    Englert H, Small-McMahon J, Chambers P, et al.: Familial risk estimation on systemic sclerosis. Aust N Z J Med 1999, 29:36–41. The first study using a large population-based study from Sydney, Australia, that formally assessed the relative risk for familial recurrence of systemic sclerosis.PubMedGoogle Scholar
  13. 13.
    Arnett FC, Cho M, Chatterjee S, et al.: Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 2001, 44:1359–1362. From Houston, Texas, and the Michigan Systemic Sclerosis Registry, this study is the first from the United States to formally estimate the familial recurrence rate of systemic sclerosis (SSc) from three large SSc cohorts.PubMedCrossRefGoogle Scholar
  14. 14.
    Laing TJ, Gillespie BW, Toth MB, et al.: Racial differences in scleroderma among women in Michigan. Arthritis Rheum 1997, 40:734–742.PubMedCrossRefGoogle Scholar
  15. 15.
    Lambert NC, Distler O, Müller-Ladner U, et al.: HLADQA1* 0501 is associated with diffuse systemic sclerosis in Caucasian men. Arthritis Rheum 2000, 43:2005–2010.PubMedCrossRefGoogle Scholar
  16. 16.
    Vlachoyiannopoulos PG, Dafni UG, Pakas I, et al.: Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele. Ann Rheum Dis 2000, 59:359–367.PubMedCrossRefGoogle Scholar
  17. 17.
    Reveille JD, Fischbach M, McNearney T, et al.: Systemic sclerosis in three U.S. ethnic groups: a comparison of clinical, sociodemographic, serologic and immunogenetic determinants. Semin Arthritis Rheum 2001, 30:332–346. The baseline report of the GENISOS study demonstrating important sociodemographic, clinical, and serologic differences among a prospective multi-ethnic systemic sclerosis cohort.PubMedCrossRefGoogle Scholar
  18. 18.
    Kuwana M, Inoko H, Kameda H, et al.: Association of human leukocyte antigen class II genes with autoantibody profiles, but not with disease susceptibility in Japanese patients with systemic sclerosis. Intern Med 1999, 38:336–344.PubMedGoogle Scholar
  19. 19.
    Susol E, Pepper C, Harrick A, et al.: Association of HLA class II genes with autoantibody production but not with disease susceptibility in UK Caucasian systemic sclerosis patients [abstract]. Arthritis Rheum 2000, 43:S263.CrossRefGoogle Scholar
  20. 20.
    Briggs D, Stephens C, Vaughan R, et al.: A molecular and serologic analysis of the major histocompatibility complex and complement component C4 in systemic sclerosis. Arthritis Rheum 1993, 36:943–954.PubMedCrossRefGoogle Scholar
  21. 21.
    Reveille JD, Brady J, MacLeod-St. Clair M, Durban E: HLA-DPB1 alleles and autoantibody subsets in systemic lupus erythematosus, Sjögren’s syndrome and progressive systemic sclerosis: a question of disease relevance. Tissue Antigens 1992, 40:45–48.PubMedCrossRefGoogle Scholar
  22. 22.
    Tan FK, Stivers DN, Arnett FC, et al.: HLA haplotypes and microsatellite polymorphisms in and around the major histocompatibility complex region in Native American population with a high prevalence of scleroderma (systemic sclerosis). Tissue Antigens 1999, 53:74–80.PubMedCrossRefGoogle Scholar
  23. 23.
    Falkner D, Wilson J, Fertig N, et al.: Studies of HLA-DR and DQ alleles in systemic sclerosis patients with autoantibodies to RNA polymerases and U3-RNP (fibrillarin). J Rheumatol 2000, 27:1196–1202.PubMedGoogle Scholar
  24. 24.
    Arnett FC, Reveille JD, Goldstein R, et al.: Autoantibodies to fibrillarin in systemic sclerosis (scleroderma): an immunogenetic, serologic, and clinical analysis. Arthritis Rheum 1996, 39:1151–1160.PubMedCrossRefGoogle Scholar
  25. 25.
    Falkner D, Wilson J, Medsger TA Jr, Morel PA: HLA and clinical associations in systemic sclerosis patients with anti-Th/To antibodies. Arthritis Rheum 1998, 41:74–80.PubMedCrossRefGoogle Scholar
  26. 26.
    Nelson JL, Furst DE, Maloney S, et al.: Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet 1998, 351:559–562.PubMedCrossRefGoogle Scholar
  27. 27.
    Artlett CM, Smith JB, Jimenez SA: Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 1998, 338:1186–1191.PubMedCrossRefGoogle Scholar
  28. 28.
    Maloney S, Smith A, Furst DE, et al.: Microchimerism of maternal origin persists into adult life. J Clin Invest 1999, 104:41–47.PubMedGoogle Scholar
  29. 29.
    Lambert NC, Bianchi DW, Johnson K, et al.: Microchimerism in systemic sclerosis [abstract]. Arthritis Rheum 2000, 43:S315.CrossRefGoogle Scholar
  30. 30.
    Lambert NC, Evans PC, Hashizumi TL, et al.: Persistent fetal microchimerism in T lymphocytes is associated with HLADQA1* 0501: implications in autoimmunity. J Immunol 2000, 164:5545–5548.PubMedGoogle Scholar
  31. 31.
    Bornstein P, Sage H: Regulation of collagen gene expression. Prog Nucleic Acid Res Mol Biol 1989, 37:67–106.PubMedCrossRefGoogle Scholar
  32. 32.
    Hitraya EG, Varga J, Artlett CM, Jimenez SA: Identification of elements in the promoter region of the _1(I) procollagen gene involved in its up-regulated expression in systemic sclerosis. Arthritis Rheum 1998, 41:2048–2058.PubMedCrossRefGoogle Scholar
  33. 33.
    Saitta B, Gaidarova S, Cicchillitti L, Jimenez SA: CCAAT binding transcription factor binds and regulates human COL1A1 promoter activity in human dermal fibroblasts. Arthritis Rheum 2000, 43:2219–2229.PubMedCrossRefGoogle Scholar
  34. 34.
    Denton CP, Zheng B, Shiwen X, et al.: Activation of a fibroblastspecific enhancer of the Pro_2(I) collagen gene in tight-skin mice. Arthritis Rheum 2001, 44:712–722.PubMedCrossRefGoogle Scholar
  35. 35.
    Ihn H, Tamaki K: Increased phosphorylation of transcription factor Sp1 in scleroderma fibroblasts. Arthritis Rheum 2000, 43:2240–2247.PubMedCrossRefGoogle Scholar
  36. 36.
    Artlett CM, Chen SJ, Varga J, Jimenez SA: Modulation of basal expression of the human alpha1(I) procollagen gene (COL1A1) by tandem NF-1/Sp1 promoter elements in normal human dermal fibroblasts. Matrix Biol 1998, 17:425–434.PubMedCrossRefGoogle Scholar
  37. 37.
    Hata RI, Akai J, Kimura A, et al.: Association of functional microsatellites in the human type I collagen _2 chain (COL1A2) gene with systemic sclerosis. Biochem Biophys Res Com 2000, 272:36–40.PubMedCrossRefGoogle Scholar
  38. 38.
    Johnson RW, Reveille JD, McNearney T, et al.: Lack of association of a functionally relevant single nucleotide polymorphism of matrix metalloproteinase-1 promoter with systemic sclerosis (scleroderma). Genes Immun 2001, 2:273–275.PubMedCrossRefGoogle Scholar
  39. 39.
    Kielty CM, Raghunath M, Siracusa LD, et al.: The tight skin mouse: demonstration of mutant fibrillin-1 production and assembly into abnormal microfibrils. J Cell Biol 1998, 140:1159–1166.PubMedCrossRefGoogle Scholar
  40. 40.
    Tan FK, Stivers DN, Foster MW, et al.: Association of microsatellite markers near the fibrillin 1 gene on human chromosome 15q with scleroderma in a Native American population. Arthritis Rheum 1998, 41:1729–1737. This important study demonstrated genetic linkage between FBN1, the mouse homologue that is abnormal in the tight skin mouse model of systemic sclerosis (SSc), and human SSc.PubMedCrossRefGoogle Scholar
  41. 41.
    Tan FK, Wang N, Kuwana M, et al.: Association of fibrillin 1 single nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum 2001, 44:893–901.PubMedCrossRefGoogle Scholar
  42. 42.
    Saito S, Nishimura H, Brumeanu T-D, et al.: Characterization of mutated protein encoded by partially duplicated fibrillin-1 gene in tight skin (tsk) mice. Mol Immunol 1999, 36:169–176.PubMedCrossRefGoogle Scholar
  43. 43.
    Wallis DD, Tan FK, Kielty CM, et al.: Abnormalities in fibrillin-1-containing microfibrils in dermal fibroblast cultures from patients with systemic sclerosis (scleroderma). Arthritis Rheum 2001, 44:1855–1864.PubMedCrossRefGoogle Scholar
  44. 44.
    Murai C, Saito S, Kasturi KN, Bona CA: Spontaneous occurrence of anti-fibrillin-1 autoantibodies in tight skin mice. Autoimmunity 1998, 28:151–155.PubMedGoogle Scholar
  45. 45.
    Tan FK, Arnett FC, Antohi S, et al.: Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connective tissue diseases. J Immunol 1999, 163:1066–1072.PubMedGoogle Scholar
  46. 46.
    Tan FK, Arnett FC, Reveille JD, et al.: Autoantibodies to fibrillin 1 in systemic sclerosis: ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles. Arthritis Rheum 2000, 43:2464–2471. This study demonstrates the specificity of antifibrillin-1 antibodies for systemic sclerosis and investigates the ethnically determined variations in recognized epitopes.PubMedCrossRefGoogle Scholar
  47. 47.
    Arnett FC, Tan FK, Uziel Y, et al.: Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin 1, in patients with localized scleroderma. Arthritis Rheum 1999, 42:2656–2659.PubMedCrossRefGoogle Scholar
  48. 48.
    Phelps RG, Daian C, Shibata S, et al.: Induction of skin fibrosis and autoantibodies by infusion of immunocompetent cells from tight skin mice into C57BL/6 pa/pa mice. J Autoimmun 1993, 6:710–718.CrossRefGoogle Scholar
  49. 49.
    McGaha T, Saito S, Phelps RG, et al.: Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R_ and transforming growth factor-_ genes. J Invest Dermatol 2001, 116:136–143.PubMedCrossRefGoogle Scholar
  50. 50.
    Siracusa LD, McGrath R, Fisher JK, Jimenez SA: The mouse tight skin (tsk) phenotype is not dependent on the presence of mature T and B lymphocytes. Mamm Genome 1998, 9:907–909.PubMedCrossRefGoogle Scholar
  51. 51.
    Dodig TD, Mack KT, Cassarino DF, Clark SH: Development of the tight-skin phenotype in immune-deficient mice. Arthritis Rheum 2001, 44:723–727.PubMedCrossRefGoogle Scholar
  52. 52.
    Rennard SI, Hunninghake GW, Bitterman PB, Crystal RG: Production of fibronectin by the human alveolar macrophage: mechanism for the recruitment of fibroblasts to sites of tissue injury in interstitial lung disease. Proc Natl Acad Sci USA 1981, 78:7147–7151.PubMedCrossRefGoogle Scholar
  53. 53.
    Avila JJ, Lympany PA, Pantelidis P, Welsh KI, et al.: Fibronectin gene polymorphisms associated with fibrosing alveolitis in systemic sclerosis. Am J Respir Cell Mol Biol 1999, 20:106–112.PubMedGoogle Scholar
  54. 54.
    Zhou XD, Stivers DN, Tan FK, Arnett FC: Secreted protein, acidic, cysteine-rich (SPARC) or osteonectin in systemic sclerosis (scleroderma): altered gene expression in dermal fibroblasts and associated microsatellite markers [abstract]. Arthritis Rheum 1999, 42:S169.Google Scholar
  55. 55.
    McCormick LL, Zhang Y, Tootell, Gilliam AC: Anti-TGF-_ treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol 1999, 163:5693–5699.PubMedGoogle Scholar
  56. 56.
    Shi-wen X, Pennington D, Holmes A, et al.: Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. Exp Cell Res 2000, 259:213–224.PubMedCrossRefGoogle Scholar
  57. 57.
    Zhou X, Tan FK, Stivers DN, Arnett FK: Microsatellites and intragenic polymorphisms of transforming growth factor _ and platelet-derived growth factor and their receptor genes in Native Americans with systemic sclerosis (scleroderma). Arthritis Rheum 2000, 43:1068–1073.PubMedCrossRefGoogle Scholar
  58. 58.
    Susol E, Rands AL, Herrick A, et al.: Association of markers for TGF _ 3, TGF _ 3 and TIMP1 with systemic sclerosis. Rheumatology (Oxford) 2000, 39:1332–1336.CrossRefGoogle Scholar
  59. 59.
    Awad MR, El-Gamel A, Hasleton P, et al.: Genotypic variation in the transforming growth factor _1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 1998, 66:1014–1020.PubMedCrossRefGoogle Scholar
  60. 60.
    Crilly A, Hamilton J, Clarke C, et al.: Analysis of TGF_1 gene polymorphisms in patients with limited and diffuse scleroderma [abstract]. Arthritis Rheum 2000, 43:S168.Google Scholar
  61. 61.
    Kawakami T, Ihn H, Xu W, et al.: Increased expression of TGF-_ receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-_ signaling to scleroderma phenotype. J Invest Dermatol 1998, 110:47–51.PubMedCrossRefGoogle Scholar
  62. 62.
    Serpier H, Gillery P, Salmon-Her V, et al.: Antagonistic effects of interferon-_ and interleukin-4 on fibroblast cultures. J Invest Dermatol 1997, 109:158–162.PubMedCrossRefGoogle Scholar
  63. 63.
    Machado RD, Pauciulo MW, Thomson JR, et al.: BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001, 68:92–102.PubMedCrossRefGoogle Scholar
  64. 64.
    Deng Z, Morse JH, Slager SL, et al.: Familial primary pulmonary hypertension (Gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000, 67:737–744.PubMedCrossRefGoogle Scholar
  65. 65.
    The International PPH Consortium: Heterozygous germline mutations in BMPR2, encoding a TGF-_ receptor, cause familial primary pulmonary hypertension. Nature Genet 2000, 26:81–84. These three articles report the linkage of familial primary pulmonary hypertension to mutations in BMPR2, which codes for a tumor growth factor-beta (TGFâ) receptor. This may represent a model for the influence of genetics on TGFâ-related phenomena in systemic sclerosis.CrossRefGoogle Scholar
  66. 66.
    Atamas SP, Yurovsky VV, Wise R, et al.: Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999, 42:1168–1178.PubMedCrossRefGoogle Scholar
  67. 67.
    Ong C, Wong C, Roberts CR, et al.: Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol 1998, 28:2619–2629.PubMedCrossRefGoogle Scholar
  68. 68.
    Sakkas LI, Tourtellotte C, Berney S, et al.: Increased levels of alternatively spliced interleukin 4 (IL-4delta2) transcripts in peripheral blood mononuclear cells from patients with systemic sclerosis. Clin Diagn Lab Immunol 1999, 6:660–664.PubMedGoogle Scholar
  69. 69.
    Youn J, Hwang S-H, Cho C-S, et al.: Association of the interleukin-4 receptor _ variant Q576R with Th1/Th2 imbalance in connective tissue disease. Immunogenetics 2000, 51:743–746.PubMedCrossRefGoogle Scholar
  70. 70.
    Bolster MB, Ludwicka A, Sutherland SE, et al.: Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 1997, 40:743–751.PubMedCrossRefGoogle Scholar
  71. 71.
    Renzoni E, Lympany P, Sestini P, et al.: Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum 2000, 43:1633–1640.PubMedCrossRefGoogle Scholar
  72. 72.
    Hasegawa M, Fujimoto M, Kikuchi K, Takahara K: Elevated serum tumor necrosis factor-_ levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol 1997, 24:663–665.PubMedGoogle Scholar
  73. 73.
    Abraham DJ, Shiwen X, Black CM, et al.: Tumor necrosis factor _ suppresses the induction of connective tissue growth factor by transforming growth factor-_ in normal and scleroderma fibroblasts. J Biol Chem 2000, 275:15220–15225.PubMedCrossRefGoogle Scholar
  74. 74.
    Pandey JP, Takeuchi F: TNF-_ and TNF-_ gene polymorphisms in systemic sclerosis. Hum Immunol 1999, 60:1128–1130.PubMedCrossRefGoogle Scholar
  75. 75.
    Pociot F, Briant L, Jongeneel CV, et al.: Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-_ and TNF-_ by human mononuclear cells: a possible link to insulindependent diabetes mellitus. Eur J Immunol 1993, 23:224–231.PubMedCrossRefGoogle Scholar
  76. 76.
    Takeuchi F, Nabeta H, Fussel M, et al.: Association of the TNFa13 microsatellite with systemic sclerosis in Japanese patients. Ann Rheum Dis 2000, 59:293–296.PubMedCrossRefGoogle Scholar
  77. 77.
    Povey A, Guppy MJ, Wood M, et al.: Cytochrome P2 polymorphisms and susceptibility to scleroderma following exposure to organic solvents. Arthritis Rheum 2001, 44:662–665.PubMedCrossRefGoogle Scholar
  78. 78.
    Tew MB, Reveille JD, Arnett FC, et al.: Glutathione Stransferase genotypes in systemic sclerosis and their association with clinical manifestations in early disease. Genes Immun 2001, 2:236–238.PubMedCrossRefGoogle Scholar
  79. 79.
    Becker KG, Simon RM, Bailey-Wilson JE, et al.: Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci USA 1998, 95:9979–9984.PubMedCrossRefGoogle Scholar
  80. 80.
    Gaffney PM, Ortmann WA, Selby SA, et al.: Genome screening in human systemic lupus erythematosus: results from a second Minnesota cohort and combined analyses of 187 sibpair families. Am J Hum Genet 2000, 66:547–556.PubMedCrossRefGoogle Scholar
  81. 81.
    Jawaheer D, Seldin MF, Amos CI, et al.: A genomewide screen in multiplex rheumatoid arthritis families suggests genetic overlap with other autoimmune diseases. Am J Hum Genet 2001, 68:927–936. This article is representative of a number of genomewide studies published recently concerning autoimmune disorders. It highlights the interesting linkage similarities reported between rheumatoid arthritis and other prototypic autoimmune diseases.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Randall W. Johnson
  • Monty B. Tew
  • Frank C. Arnett
    • 1
  1. 1.Department of Internal MedicineUniversity of Texas Health Science CenterHoustonUSA

Personalised recommendations